Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy “REGATТA” results)

Abstract

Introduction.Upper gastrointestinal (UGI) bleeding is a common complication of antiplatelet therapy. Data from real clinical practice that characterize the range of risk factors for UGI bleeding, prophylactic proton pump inhibitors (PPIs) therapy, bleeding frequency and their long-term effects in patients with stable coronary artery disease (CAD) are limited.
 Aim.To identify predictors of UGI bleeding in patients with stable CAD, to assess the role of PPI in the prevention of bleeding and the long-term prognosis of patients after bleeding.
 Materials and methods.934 patients with stable CAD (median age 61 [5368] years, 78.6% men) were included in the single institution prospective REGistry of Long-term AnTithrombotic TherApy (REGATTA). Atherosclerosis of peripheral arteries (APA) and abdominal aortic aneurysm (AAA) screening was performed by doctor decision, as well as esophagogastroduodenoscopy. 76% of patients received dual antiplatelet therapy for 612 months after elective PCI. PPIs were prescribed in 28.3% of cases.
 Results.The median follow-up was 2.5 [1.15.1] years. The frequency of overt UGI bleeding was 1.9 per 100 patients per year. Anamnesis of peptic ulcer disease (OR 4.7; 95% CI 1.911.8;p=0.001), erosion of the upper gastrointestinal tract (OR 6.7; 2.716.6;p=0.00004 ), as well as concomitant diseases associated with a decrease in blood supply to the mucosa, such as heart failure HF (OR 6.1; 2.316.0;p=0.0002), AAA (OR 9.3; 2.534.2;p=0.0008) and APA (OR 2.3; 0.985.5;p=0.05) turned out to be independent predictors of UGI bleeding. The frequency of AAA among those who underwent UGI bleeding was 19.6% (in patients without bleeding 1.4%;p0.001). 90.2% of patients with UGI bleeding received PPI; the frequency of UGI bleeding in patients receiving pantoprazole and omeprazole did not differ significantly. After UGI bleeding, rebleeding rate was 7.8%, thrombotic events (TE) rate 31.4%, mortality rate 17.7% for 30 days, 19.4% for 1 year and 35.3% for the entire observation period. The predictors of deaths were AAA (OR 92.5; 7.7107.9;p0.0001), APA (OR 4.2; 1.0317.2;p=0.045) and HF (OR 34.5; 8.5140.6;p0.0001). The worst prognosis was expected for patients who underwent UGI bleeding and thrombotic events: 2/3 of these patients died.
 Conclusion.In a prospective analysis of patients with stable CAD, we identified UGI bleeding was a significant risk factor for late thromboembolism and death, compared with patients without bleeding. Predictors of UGI bleeding and poor prognosis are factors that indicate atherothrombotic burden abdominal aortic aneurysm, peripheral atherosclerosis and HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04347200.

Risk factors and outcomes of gastrointestinal bleeding in patients with stable coronary artery disease: data from the observational registry of long-term antithrombotic therapy REGATTA-1

“…Сравнение предсказательной ценности разработанной нами шкалы риска развития ЖКК со шкалой ЕОК 2015г [4] [5]).…”

“…Обcуждение ЖКК занимают лидирующие позиции в структуре геморрагических осложнений у больных, получающих антиагрегантные препараты. Прогноз больных с различными проявлениями атеротромбоза, перенесших такие кровотечения, считается неблагоприятным: смертность в течение года после любого клинически значимого эпизода ЖКК составляет 20-25% [1,5].…”

“…Ранее нами было показано [5], что исходы больных, перенесших ЖКК, определяются высокой частотой ТО, в то время как случаев рецидивов кровотечений было существенно меньше. Анализ когорты больных, подвергнутых плановым ЧКВ и получавших в связи с этим исходную терапию двумя антиагрегантами (рис.…”

“…Для создания шкалы риска кровотечений из верхних отделов ЖКТ и оценки ее прогностической ценности использовалась когорта пациентов со стабильной ИБС, включенных в одноцентровой проспективный регистр длительной антитромботической терапии РЕГАТА [5], созданный на базе ФГБУ НМИЦ Кардиологии Минздрава России -рисунок 1. В рамках данного исследования анализировались пациенты, включенные в период с 2003 по 2019гг.…”

“…Критерии включения и исключения были подробно описаны в наших предыдущих публикациях [5]. Коротко отметим, что в исследование включа-(ClinicalTrials.gov Identifier: NCT04347200).…”